test
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded in 2011 and is headquartered in Princeton, New Jersey.
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded in 2011 and is headquartered in Princeton, New Jersey.
Ordem cancelada
